Treatment Action Group: CROI 2026 TB Research Round Up

12 March 2026

The 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) took place in Denver, USA, on 22-25 February 2026.

Treatment Action Group (TAG) released an overview of TB research data reported at CROI 2026. Highlights include results from several studies that answered questions on how to give 3HP and 1HP with the HIV medicine dolutegravir (including data for children and pregnant persons); insights into a targeted linezolid dosing strategy; and preclinical data on long-acting pretomanid and TBAJ-876 (sorfequiline). A plenary session on the last day of the conference focused on the major progress made in closing TB treatment and diagnostic evidence gaps for children and the importance of including children and mothers early in clinical research.

A summary of major findings and TAG’s analysis are available here.

Source: Treatment Action Group